• Latest Posts

Calliditas reveals ‘encouraging results’ from head and neck cancer trial 

Calliditas shares rise as phase 3 endpoints met in kidney disease trial

5 advancements in kidney disease research over the past year

First treatment of rare kidney disease launched in Germany by STADA Arzneimittel

Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug

Industry Perspectives: Women in Biotech 2019